Formulations with lipid systems carrying bioactive compounds for use as an immunotherapy potentiator or adjuvant for patients with cancer or immunological disorders

Abstract

The present invention relates to a lipid system which not only improves stability during digestion and oral bioavailability of various bioactive compounds in a safe and effective manner, but also in many cases enhances the effects of said compounds. The present invention also relates to formulations or compositions comprising lipid systems carrying bioactive compounds for use as immunotherapy potentiators or adjuvants for patients with cancer or immunological disorders.

1 . A composition comprising a supercritical rosemary extract (SRE) and a lipid system in turn comprising ratfish liver oil (RLO) or the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil (RLO). 
     
     
         2 . The composition according to  claim 1 , where said composition comprises ratfish liver oil (RLO) and SRE. 
     
     
         3 . The composition according to  claim 2 , where said composition further comprises monoglycerides or further comprises between 2 and 30% w/w of monoglycerides. 
     
     
         4 . The composition according to  claim 3 , where said monoglycerides are selected from the group consisting of monoolein (MO) and monostearin (MS). 
     
     
         5 . The composition according to  claim 4 , where said monoglyceride is MS. 
     
     
         6 . The composition according to  claim 5 , where said composition consists of +/−30% of a composition comprising:
 a. 91.2% w/w of RLO, 
 b. 5.2% w/w of SRE, and 
 c. 3.6% w/w of MS. 
 
     
     
         7 . The composition according to  claim 1 , where the lipid system is the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil, wherein the lipid system comprises:
 a. between 25% and 35% (w/w) of monoglycerides and/or free alkylglycerols;   b. between 10% and 25% (w/w) of diacylglycerol ethers (DAGEs); and   c. between 40% and 60% (w/w) of monoacylglycerol ethers (MAGEs) and/or diacylglycerols (DAGs), where the proportion of MAGEs with respect to the total amount of MAGEs and DAGs present in the lipid system is at least 50% (w/w).   
     
     
         8 . The composition according to  claim 1 , where the lipid system is the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil, wherein the lipid system comprises:
 a. between 25% and 35% (w/w) of monoglycerides and/or free alkylglycerols;   b. between 10% and 25% (w/w) of diacylglycerol ethers (DAGEs);   c. between 0 and 5% (w/w) of triglycerides;   d. between 0 and 3% of glycerin; and   e. between 40% and 60% (w/w) of monoacylglycerol ethers (MAGEs) and/or diacylglycerols (DAGs), where the proportion of MAGEs with respect to the total amount of MAGEs and DAGs present in the lipid system is at least 50% (w/w).   
     
     
         9 . The composition according to  claim 1 , where the lipid system is the product of an enzymatic or chemical glycerolysis process based on ratfish liver oil, wherein the lipid system comprises:
 a. between 28% and 32% (w/w) of monoglycerides and/or free alkylglycerols;   b. between 18% and 22% (w/w) of diacylglycerol ethers (DAGEs);   c. between 0 and 2% (w/w) of triglycerides;   d. between 1% and 3% of glycerin; and   e. between 40% and 50% (w/w) of monoacylglycerol ethers (MAGEs) and/or diacylglycerols (DAGs), where the proportion of MAGEs with respect to the total amount of MAGEs and DAGs present in the lipid system is at least 50% (w/w).   
     
     
         10 . A method of treating a patient having cancer or immunological disorder comprising administering the composition of  claim 1  as an immunotherapy potentiator or adjuvant. 
     
     
         11 . The method according  claim 10 , wherein the patient has an autoimmune-based immunological disorder selected from the group consisting of: rheumatoid arthritis, type I diabetes, psoriasis, celiac disease and multiple sclerosis. 
     
     
         12 . The method according to  claim 10 , wherein the patient has a tumor growth, chronic lymphocytic choriomeningitis virus infection, hepatitis (B and C) virus infection, or human immunodeficiency virus infection. 
     
     
         13 . The method according to  claim 10 , wherein the treatment prevents kidney damage. 
     
     
         14 . The composition according to  claim 1 , wherein the composition is formulated as a pharmaceutically acceptable or food-grade vehicle for functional foods, nutraceutical products, natural extracts, drugs, or anticancer drugs. 
     
     
         15 . A food composition comprising the composition of  claim 1 . 
     
     
         16 . A pharmaceutical composition comprising the composition of  claim 1  and one or more pharmaceutically acceptable excipients.